Corticosteroid therapy in regressive autism: Preliminary findings from a retrospective study

BMC Medicine

John A Sweeney²  Sailaja Golla¹ 

[1] Division of Pediatric Neurology, Neurodevelopmental Pediatrics, UT Southwestern and Children's Medical Center at Dallas, Dallas, USA;Center for Autism and Developmental Disabilities, UT Southwestern and Children’s Medical Center at Dallas, Dallas, USA

关键词: Behavior;    Language;    FMAER;    Corticosteroids;    Regression;    Autism;   

Others  :  854885
DOI  :  10.1186/1741-7015-12-79

 received in 2014-04-23, accepted in 2014-04-23,  发布年份 2014

【 摘 要 】

Some children with autism spectrum disorders (ASD; 15% to 30% of patients) show a significant and persistent regression in speech and social function during early childhood. There are no established treatments for the regressive symptoms. However, there are some known causes of this type of regression, such as Rett syndrome and Landau-Kleffner syndrome (LKS). In LKS, steroids have been used as a treatment. Some evidence suggests an autoimmune contribution to the pathophysiology of autism (Chez MG, Guido-Estrada N: Immune therapy in autism: historical experience and future directions with immunomodulatory therapy. Neurotherapeutics 2010, 7:293–301, Wasilewska J, Kaczmarski M, Stasiak-Barmuta A, Tobolczyk J, Kowalewska E: Low serum IgA and increased expression of CD23 on B lymphocytes in peripheral blood in children with regressive autism aged 3-6 years old. Arch Med Sci 2012, 8:324–331, Stefanatos G: Changing perspectives on Landau-Kleffner syndrome. Clin Neuropsychol 2011, 25:963–988), raising the possibility that steroids might be a useful therapy for regression in ASD. A retrospective study published in BMC Neurology by Duffy et al. (Duffy, et al: Corticosteroid therapy in regressive autism: A retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior. BMC Neurol 2014, 14:70) reviewed 20 steroid treated R-ASD (STAR) patients and 24 ASD control patients not treated with steroids (NSA). Improvements in clinical function and in a neurophysiological biomarker were seen in the steroid-treated children pre- to post-prednisolone treatment. This research provides a rationale for a randomized trial with steroid therapy to determine the longer term benefits and complications of steroids in this population.

Please see related article http://www.biomedcentral.com/1471-2377/14/70/abstract webcite.

【 授权许可】

   
2014 Golla and Sweeney; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Rogers SJ: Developmental regression in autism spectrum disorders. Ment Retard Dev Disabil Res Rev 2004, 10:139-143.
• [2]Barger BD, Campbell JM, McDonough JD: Prevalence and onset of regression within autism spectrum disorders: a meta-analytic review. J Autism Dev Disord 2013, 43:817-828.
• [3]Cohly HH, Panja A: Immunological findings in autism. Int Rev Neurobiol 2005, 71:317-341.
• [4]Chez MG, Guido-Estrada N: Immune therapy in autism: historical experience and future directions with immunomodulatory therapy. Neurotherapeutics 2010, 7:293-301.
• [5]Wasilewska J, Kaczmarski M, Stasiak-Barmuta A, Tobolczyk J, Kowalewska E: Low serum IgA and increased expression of CD23 on B lymphocytes in peripheral blood in children with regressive autism aged 3-6 years old. Arch Med Sci 2012, 8:324-331.
• [6]Stefanatos G: Changing perspectives on Landau-Kleffner syndrome. Clin Neuropsychol 2011, 25:963-988.
• [7]Shenoy S, Arnold S, Chatila T: Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J Pediatr 2000, 136:682-687.
• [8]Duffy , et al.: Corticosteroid therapy in regressive autism: A retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior. BMC Neurol 2014, 14:70.
• [9]Duffy FH, Eksioglu YZ, Rotenberg A, Madsen JR, Shankardass A, Als H: The frequency modulated auditory evoked response (FMAER), a technical advance for study of childhood language disorders: cortical source localization and selected case studies. BMC Neurol 2013, 13:12. BioMed Central Full Text